Based on recent data, MoonLake Immunotherapeutics (MLTX) shows an Average True Range (ATR) of 1.05 and an Enterprise Value of 2.2B. Its average trading volume over the past 3 months is 1.02M, indicating liquidity. These fundamental metrics provide insight into MLTX's underlying financial health and market activity.
| ATR | 1.05 |
| Enterprise Value | 2.2B |
| Avg Vol (3 Months) | 1.02M |
| Avg Vol (10 Days) | 1.48M |
MoonLake Immunotherapeutics (MLTX) technical indicators as of June 23, 2026: the SMA 20 is 6.32%, SMA 50 at 14.08%, and SMA 200 at -42.56%. The RSI 14 value is 58.23, suggesting its current momentum. These technical analysis signals help assess MLTX's price trends and potential future movements.
| SMA 20 | 6.32% |
| SMA 50 | 14.08% |
| SMA 200 | -42.56% |
| RSI 14 | 58.23 |
MoonLake Immunotherapeutics (MLTX) stock performance overview as of June 23, 2026: The 52-week high is $62.75 (currently -71.82% below), and the 52-week low is $5.95 (currently 197.14% above). Over the past year, MLTX's performance is -60.62%, compared to the S&P 500's 10.67% change.
| 52-Week High | 62.75 |
| 52-Week High Chg | -71.82% |
| 52-Week Low | 5.95 |
| 52-Week Low Chg | +197.14% |
| S&P 500 52-Week Chg | 10.67% |
According to market data, MoonLake Immunotherapeutics (MLTX) stock's recent performance metrics show that over the last month, MLTX is 17.06%, with a Year-to-Date (YTD) performance of 23.9%. Over the past year, the stock has seen a -60.62% change. These figures summarize MLTX's price movements across various periods, reflecting its historical returns.
| Period | 1 Week | 1 Month | Quarter | Half Year | 1 Year | YTD |
|---|---|---|---|---|---|---|
| High | 23.29 | 23.29 | 23.29 | 23.29 | 62.75 | 23.29 |
| Low | 18.23 | 16.53 | 15.76 | 11.06 | 5.95 | 11.06 |
| Performance | -9.73% | +17.06% | +79.06% | -69.52% | -60.62% | +23.90% |
According to current financial data, MLTX stock's P/E (TTM) ratio is -5.68, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.22. Key valuation ratios for MLTX, including P/S (N/A), P/B (6.19), and P/FCF (-7.24), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.
| Valuation | MLTX | Sector Median | Industry Avg | S&P 500 |
|---|---|---|---|---|
| P/E (TTM) | -5.68 | -1.22 | -5.02 | 32.59 |
| P/S (TTM) | N/A | 3.69 | 462.04 | 5.98 |
| P/B (TTM) | 6.19 | 0.05 | 12.18 | 5 |
| P/FCF (TTM) | -7.24 | -11.65 | -908.56 | 28.32 |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep